Cargando…

Cancer testis antigen and immunotherapy

The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishnadas, Deepa Kolaseri, Bai, Fanqi, Lucas, Kenneth G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928360/ https://www.ncbi.nlm.nih.gov/pubmed/27471684 http://dx.doi.org/10.2147/ITT.S35570

Ejemplares similares

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy
por: Huang, Michael A., et al.
Publicado: (2015)

Oncogenic cancer/testis antigens: prime candidates for immunotherapy
por: Gjerstorff, Morten F., et al.
Publicado: (2015)

Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2015)

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
por: Xu, Yichi, et al.
Publicado: (2020)

Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy
por: Zhang, Yujie, et al.
Publicado: (2019)

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects()
por: Wei, Xiao, et al.
Publicado: (2019)

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers
por: Ai, Huihan, et al.
Publicado: (2023)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1): A Promising Cancer Testis Antigen
por: Bai, Rui, et al.
Publicado: (2022)

Targeting cancer testis antigens in synovial sarcoma
por: Mitchell, Geoffrey, et al.
Publicado: (2021)

Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer
por: Nin, Dawn Sijin, et al.
Publicado: (2023)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
por: Albertsmeier, Markus, et al.
Publicado: (2020)

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
por: Yousef, Sara, et al.
Publicado: (2015)

Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy
por: Shim, Kyeonghee, et al.
Publicado: (2023)

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
por: Xie, Kaipeng, et al.
Publicado: (2019)

The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy
por: Smith, Heath A., et al.
Publicado: (2010)

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy
por: Mirandola, Leonardo, et al.
Publicado: (2017)

Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma
por: Grizzi, Fabio, et al.
Publicado: (2007)

Cancer/testis antigens and gametogenesis: a review and "brain-storming" session
por: Kalejs, Martins, et al.
Publicado: (2005)

TARP as antigen in cancer immunotherapy
por: Vanhooren, Jolien, et al.
Publicado: (2021)

The Price of Human Evolution: Cancer-Testis Antigens, the Decline in Male Fertility and the Increase in Cancer
por: Erenpreisa, Jekaterina, et al.
Publicado: (2023)

Inducible expression of cancer-testis antigens in human prostate cancer
por: Heninger, Erika, et al.
Publicado: (2016)

Cancer-testis antigen expression and immunogenicity in AL amyloidosis
por: Rosenzweig, M A, et al.
Publicado: (2012)

Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading
por: Miyamoto, Ai, et al.
Publicado: (2022)

Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer
por: Xie, Xiaodong, et al.
Publicado: (2023)

Emerging roles of cancer-testis antigenes, semenogelin 1 and 2, in neoplastic cells
por: Shuvalov, Oleg, et al.
Publicado: (2021)

Cancer-Testis Antigens in Triple-Negative Breast Cancer: Role and Potential Utility in Clinical Practice
por: Lam, Runyi Adeline, et al.
Publicado: (2021)

Role and Clinical Utility of Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma
por: Wu, Sharon Changshan, et al.
Publicado: (2021)

Antigen processing and presentation in cancer immunotherapy
por: Lee, Maxwell Y, et al.
Publicado: (2020)

Pattern of cancer/testis antigen expression in lung cancer patients
por: KIM, YEONG-DAE, et al.
Publicado: (2012)

Cancer testis antigens: A new paradigm for cancer therapy
por: Suri, Anil, et al.
Publicado: (2012)

Cancer/testis antigens (CTAs) expression in resected lung cancer
por: Jin, Shi, et al.
Publicado: (2018)

Characterization of Cancer/Testis Antigens as Prognostic Markers of Ovarian Cancer
por: Vlasenkova, Ramilia, et al.
Publicado: (2023)

Inducible expression of antigen processing and antigen presentation molecules and cancer testis antigens in human prostate cancer
por: Heninger, Erika, et al.
Publicado: (2015)

Human Tumor Antigens and Cancer Immunotherapy
por: Vigneron, Nathalie
Publicado: (2015)

The Novelty of Human Cancer/Testis Antigen Encoding Genes in Evolution
por: Dobrynin, Pavel, et al.
Publicado: (2013)

Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma
por: Freitas, Marcelo Roberto Pereira, et al.
Publicado: (2013)

Integrative Discovery of Epigenetically Derepressed Cancer Testis Antigens in NSCLC
por: Glazer, Chad A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_roan3qt3ndesdcoi7uld2opvl6